FTSE 100 news / Companies and sectors / AstraZeneca / Guardant360 CDx approved in Europe as companion diagnostic for camizestrant

Guardant360 CDx approved in Europe as companion diagnostic for camizestrant

+8.1 strongly positive

Guardant's assay gains CE mark as companion diagnostic for AstraZeneca's camizestrant.

3 headlines from 3 outlets, from 9 October 2026 to 10 October 2026. The story's tone is the average of its headlines' own scores.

How each outlet covered it

Average tone of each outlet's headlines in this story. One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.

Outlet	Headlines	Tone
Yahoo Finance	1	+9.2
Genome Web	1	+7.5
Securities.io	1	+7.5

Day by day

Saturday 10 October 2026 2 headlines

Guardant's assay gains CE mark as companion diagnostic for AstraZeneca's camizestrant.

+7.5 Guardant Health Assay Nabs CE Mark as CDx for AstraZeneca’s Etcamah in Breast Cancer Genome Web
CE mark for diagnostic paired with AstraZeneca's breast cancer drug.
+7.5 Guardant360 CDx Gains CE Mark as Camizestrant Companion Diagnostic Securities.io
Companion diagnostic CE mark supports camizestrant, AstraZeneca's drug.

Friday 9 October 2026 1 headline

Guardant Health announced EU approval of Guardant360 CDx as companion diagnostic for camizestrant.

+9.2 Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer Yahoo Finance
EU companion diagnostic approval supports camizestrant launch in Europe

AstraZeneca: all news analysis · Sector · FTSE 100 news